Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study

被引：2

作者：

Feugier, Pierre ^{[1
]}

Brice, Pauline ^{[2
]}

Maynadie, Marc ^{[3
]}

Franchi-Rezgui, Patricia ^{[4
]}

Hacini, Maya ^{[5
]}

Laurent, Guy ^{[6
]}

Suc, Etienne ^{[7
]}

Fitoussi, Olivier ^{[8
]}

Solal-Celigny, Philippe ^{[9
]}

Damaj, Ghandi ^{[10
]}

Haioun, Corinne ^{[11
]}

Leconte, Pierre ^{[12
]}

Lazreg, Fatima ^{[12
]}

Boissard, Federic ^{[12
]}

Pau, David ^{[12
]}

Salles, Gilles ^{[13
]}

机构：

[1] CHU Nancy, Dept Hematol, Vandoeuvre Les Nancy, France

[2] Univ Paris VII, Hosp St Louis, APHP, Dept Hematol, Paris, France

[3] CHU Dijon, Dept Biolof Hematol, Dijon, France

[4] Univ Paris VI, Hosp Cochin, APHP, Dept Hematol, Paris, France

[5] Hosp Ctr Chambery, Dept Hematol, Chambery, France

[6] Hosp Purpan, Dept Hematol, Toulouse, France

[7] Clin Pont Chaume, Dept Hematol, Montauban, France

[8] Polyclin Bordeaux Nord Aquitaine, Dept Hematol, Bordeaux, France

[9] Western Canc Inst, Dept Hematol, Nantes, France

[10] CHU Caen, Dept Hematol, Caen, France

[11] Hosp Henri Mondor, Dept Hematol, Creteil, France

[12] Roche, Boulogne, France

[13] Univ Claude Bernard Lyon 1, Civil Hosp Lyon, Dept Hematol, Pierre Benite, France

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 10期

关键词：

NON-HODGKINS-LYMPHOMA; RITUXIMAB MAINTENANCE; RESPONSE DURATION; THERAPY; PHASE-3;

D O I：

10.1080/10428194.2018.1434878

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2485 / 2488

页数：4

共 12 条

[1] B-cell receptor pathway modulators in NHL [J].

Blum, Kristie A. .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, :82-91

[2] Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Dreyling, M. ;

Ghielmini, M. ;

Rule, S. ;

Salles, G. ;

Vitolo, U. ;

Ladetto, M. .

ANNALS OF ONCOLOGY, 2016, 27 :v83-v90

[3] Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) [J].

Forstpointner, Roswitha ;

Unterhalt, Michael ;

Dreyling, Martin ;

Boeck, Hans-Peter ;

Repp, Roland ;

Wandt, Hannes ;

Pott, Christiane ;

Seymour, John F. ;

Metzner, Bernd ;

Haenel, Annette ;

Lehmann, Tanja ;

Hartmann, Frank ;

Einsele, Hermann ;

Hiddemann, Wolfgang .

BLOOD, 2006, 108 (13) :4003-4008

[4] Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly X 4 schedule [J].

Ghielmini, M ;

Schmitz, SFH ;

Cogliatti, SB ;

Pichert, G ;

Hummerjohann, J ;

Waltzer, U ;

Fey, MF ;

Betticher, DC ;

Martinelli, G ;

Peccatori, F ;

Hess, U ;

Zucca, E ;

Stupp, R ;

Kovacsovics, T ;

Helg, C ;

Lohri, A ;

Bargetzi, M ;

Vorobiof, D ;

Cerny, T .

BLOOD, 2004, 103 (12) :4416-4423

[5] Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the minnie pearl cancer research network [J].

Hainsworth, JD ;

Litchy, S ;

Shaffer, DW ;

Lackey, VL ;

Grimaldi, M ;

Greco, EA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1088-1095

[6] Intensive therapies in follicular non-Hodgkin lymphomas [J].

Hunault-Berger, M ;

Ifrah, N ;

Solal-Celigny, P .

BLOOD, 2002, 100 (04) :1141-1152

[7]

Roche Registration Ltd, 2017, MAB THER SUMM PROD C

[8] Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [J].

Salles, Gilles ;

Seymour, John Francis ;

Offner, Fritz ;

Lopez-Guillermo, Armando ;

Belada, David ;

Xerri, Luc ;

Feugier, Pierre ;

Bouabdallah, Reda ;

Catalano, John Vincent ;

Brice, Pauline ;

Caballero, Dolores ;

Haioun, Corinne ;

Pedersen, Lars Moller ;

Delmer, Alain ;

Simpson, David ;

Leppa, Sirpa ;

Soubeyran, Pierre ;

Hagenbeek, Anton ;

Casasnovas, Olivier ;

Intragumtornchai, Tanin ;

Ferme, Christophe ;

da Silva, Maria Gomes ;

Sebban, Catherine ;

Lister, Andrew ;

Estell, Jane A. ;

Milone, Gustavo ;

Sonet, Anne ;

Mendila, Myriam ;

Coiffier, Bertrand ;

Tilly, Herve .

LANCET, 2011, 377 (9759) :42-51

[9] Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial [J].

Sehn, Laurie H. ;

Chua, Neil ;

Mayer, Jiri ;

Dueck, Gregg ;

Trneny, Marek ;

Bouabdallah, Kamal ;

Fowler, Nathan ;

Delwail, Vincent ;

Press, Oliver ;

Salles, Gilles ;

Gribben, John ;

Lennard, Anne ;

Lugtenburg, Pieternella J. ;

Dimier, Natalie ;

Wassner-Fritsch, Elisabeth ;

Fingerle-Rowson, Guenter ;

Cheson, Bruce D. .

LANCET ONCOLOGY, 2016, 17 (08) :1081-1093

[10] Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study [J].

van Oers, Marinus H. J. ;

Van Glabbeke, Martine ;

Giurgea, Livia ;

Klasa, Richard ;

Marcus, Robert E. ;

Wolf, Max ;

Kimby, Eva ;

van t Veer, Mars ;

Vranovsky, Andrej ;

Holte, Harald ;

Hagenbeek, Anton .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) :2853-2858

← 1 2 →